Validation of Gallium-68 PSMA-PET/CT for primary lymph node staging in prostate cancer patients

Kalmthout, Ludwike van; Melick, H. Van; Lavalaye, Jules; Kooistra, A.; Klerk, John de; Meijer, Richard P.; Keizer, Bart de; Lam, Marnix G. E. H.

doi:10.1016/s1569-9056(19)31410-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years Prostate Specific Membrane Antigen receptor (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) has rapidly evolved as a corner stone in prostate cancer imaging. PSMA PET/CT outperforms other imaging modalities due to its superior sensitivity and specificity, although sensitivity for lymph node metastases has been found to be moderate in prospective trials (1,2,3,4,5). The better diagnostic characteristics account for better treatment selection in both primary staging as well as biochemical recurrence.…”

Section: Introductionmentioning

confidence: 99%

Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions

et al. 2021

View full text Add to dashboard Cite

IntroductionTens of different Prostate Specific Membrane Antigen (PSMA) targeting radiopharmaceuticals for both imaging and therapy have been synthesized. Although variability in biodistribution and affinity for binding to the PSMA receptor between different PSMA targeting radiopharmaceuticals are known, little is known about the clinical implications of those variabilities. Therefore, in this study differences in interreader agreement and detection rate between two regularly used 18 F-labeled PSMA-receptor targeting radiopharmaceuticals [ 18 F]-DCFPyL and [ 18 F]-PSMA-1007 were analyzed. Material and methods One hundred and twenty consecutive patients scanned with [ 18 F]-PSMA-1007 were match-paired with 120 patients scanned with [ 18 F]-DCFPyL. All 240 PET/CTs were reviewed by two readers and scored according to PSMA-RADS reading criteria for PSMA PET/CT. Inter-reader agreement and detection rate of suspected lesions were scored for different anatomical locations including prostate/prostatic fossa, lymph nodes, bone, and other locations. ResultsLarge equality between [ 18 F]-DCFPyL and [ 18 F]-PSMA-1007 was found; however, some clinically relevant and statistically significant differences were observed. [ 18 F]-PSMA-1007 detected suspected prostatic/prostatic fossa lesions in a higher proportion of patients and especially in the subcohort of patients scanned for biochemical recurrence. [ 18 F]-DCFPyL and [ 18 F]-PSMA-1007 showed equal ability for detection of suspected lymph nodes, although inter-reader agreement for [ 18 F]-DCFPyL was higher. [ 18 F]-DCFPyL showed less equivocal skeletal lesions and higher inter-reader agreement for skeletal lesions.The majority of equivocal lesions found with PSMA-1007 (at least were determined to be aof nonmetastatic origin. ConclusionClinically relevant differences, which may account for diagnostic dilemmas, were observed between of [ 18 F]-DCFPyL and [ 18 F]-PSMA-1007. Those findings encourage further studies, as they may have consequences for selection of the proper PSMA targeting radiopharmaceutical.

show abstract

Section: Introductionmentioning

confidence: 99%

Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions

et al. 2021

View full text Add to dashboard Cite

show abstract

Validation of Gallium-68 PSMA-PET/CT for primary lymph node staging in prostate cancer patients

Cited by 1 publication

References 0 publications

Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions

Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions

Contact Info

Product

Resources

About

Validation of Gallium-68 PSMA-PET/CT for primary lymph node staging in prostate cancer patients

Cited by 1 publication

References 0 publications

Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions

Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions

Contact Info

Product

Resources

About

Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions

Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions